艾德生物
(300685)
| 流通市值：79.79亿 | | | 总市值：80.50亿 |
| 流通股本：3.90亿 | | | 总股本：3.93亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 272,090,793.91 | 1,108,948,700.11 | 847,967,831.38 | 543,017,402.22 |
| 营业收入 | 272,090,793.91 | 1,108,948,700.11 | 847,967,831.38 | 543,017,402.22 |
| 二、营业总成本 | 171,878,070.83 | 793,982,033.11 | 596,597,050.32 | 383,540,305.43 |
| 营业成本 | 44,947,949.58 | 169,145,096.25 | 129,440,425.59 | 80,621,369.42 |
| 税金及附加 | 3,276,001.9 | 5,003,157.54 | 3,704,087.49 | 2,556,098.98 |
| 销售费用 | 71,810,221.37 | 358,816,272.74 | 252,002,610.11 | 160,378,604.52 |
| 管理费用 | 20,682,579.95 | 72,214,299.19 | 58,257,058.21 | 44,033,803.71 |
| 研发费用 | 41,536,126.88 | 216,114,223.25 | 164,361,893.33 | 106,212,012.43 |
| 财务费用 | -10,374,808.85 | -27,311,015.86 | -11,169,024.4 | -10,261,583.63 |
| 其中:利息费用 | 336,303.08 | 1,339,204.65 | 906,160.56 | 508,587.68 |
| 其中:利息收入 | 7,353,176.83 | 26,579,322.2 | 19,560,759.61 | 12,836,353.81 |
| 加:公允价值变动收益 | 1,814,123.84 | 8,768,533.37 | 6,409,871.62 | 4,637,822.22 |
| 加:投资收益 | -706,707.39 | -9,254,440.03 | -229,685.66 | 499,365.75 |
| 资产处置收益 | -151,135.17 | -1,063,253.41 | 15,576.72 | 7,064.41 |
| 资产减值损失(新) | 66,217.25 | -8,150,640.86 | -7,967,978.99 | -7,959,455.81 |
| 信用减值损失(新) | -1,600,193.06 | -30,218,314.54 | -7,794,373.01 | -5,454,971.33 |
| 其他收益 | 2,447,782.86 | 17,929,432.91 | 11,399,317.93 | 8,963,678.72 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 102,082,811.41 | 292,977,984.44 | 253,203,509.67 | 160,170,600.75 |
| 加:营业外收入 | 5,000.92 | 176,975.13 | 45,576.79 | 41,025.79 |
| 减:营业外支出 | 294,312.21 | 3,274,297.22 | 2,142,440.55 | 1,787,533.71 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 101,793,500.12 | 289,880,662.35 | 251,106,645.91 | 158,424,092.83 |
| 减:所得税费用 | 11,321,721.6 | 35,017,217.4 | 23,836,108.42 | 14,567,526.82 |
| 六、净利润 | 90,471,778.52 | 254,863,444.95 | 227,270,537.49 | 143,856,566.01 |
| 持续经营净利润 | 90,471,778.52 | 254,863,444.95 | 227,270,537.49 | 143,856,566.01 |
| 归属于母公司股东的净利润 | 90,471,778.52 | 254,863,444.95 | 227,270,537.49 | 143,856,566.01 |
| (一)基本每股收益 | 0.23 | 0.64 | 0.57 | 0.36 |
| (二)稀释每股收益 | 0.23 | 0.64 | 0.57 | 0.36 |
| 八、其他综合收益 | - | -204,431.24 | 56,809.94 | -553,194.26 |
| 归属于母公司股东的其他综合收益 | - | -204,431.24 | 56,809.94 | -553,194.26 |
| 九、综合收益总额 | 90,471,778.52 | 254,659,013.71 | 227,327,347.43 | 143,303,371.75 |
| 归属于母公司股东的综合收益总额 | 90,471,778.52 | 254,659,013.71 | 227,327,347.43 | 143,303,371.75 |
| 公告日期 | 2025-04-22 | 2025-04-22 | 2024-10-22 | 2024-07-30 |
| 审计意见(境内) | | 标准无保留意见 | | |